Drug intelligence / Profile preview

PLX-MS

Development stage: Preclinical
Lead developer: Pluri
Modality: Cell Therapies

Overview

PLX-MS is an investigational allogeneic cell therapy composed of placenta-derived mesenchymal-like adherent stromal cells developed by Pluristem Therapeutics for the prevention and treatment of multiple sclerosis. Preclinical studies suggest that these PLX cells exert immunomodulatory and neuroprotective effects by secreting anti-inflammatory cytokines and trophic factors, shifting immune responses away from pathogenic autoimmunity and potentially limiting demyelination and neurodegeneration in experimental autoimmune encephalomyelitis models.【16】

Beyond the preview

Go deeper on PLX-MS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLX-MS.

Explore the full profile